István Láng

9.1k citations

121 papers · 4.6k · 1 hit paper · h-index 27

Impact in

Oncology top 1%
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
Cancer Research top 1%
- Breast Cancer Treatment Studies

Papers in

Pulmonary and Respiratory Medicine 41
- Advanced Breast Cancer Therapies 23
Oncology 40
- HER2/EGFR in Cancer Research 16
- Cancer Treatment and Pharmacology 14

Co-authors: Sophia Randolph (6 shared papers)John Crown (6 shared papers)Richard S. Finn (6 shared papers)Katalin Boér (6 shared papers)Xin Huang (5 shared papers)Sindy T. Kim (3 shared papers)Tamás Pintér (4 shared papers)Ravindranath Patel (3 shared papers)
Journals: Journal of Clinical Oncology (21 papers)Cancer Research (10 papers)Annals of Oncology (4 papers)Immunopharmacology (3 papers)Immunology Letters (3 papers)
Partner nations: Hungary United States Belgium

In The Last Decade

István Láng

115 papers receiving 4.4k citations

István Láng's Hit Papers

align trajectories log scale

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study 2014 · 1.5k citations

Peers

Countries citing papers authored by István Láng

Since Specialization

Citations

This map shows the geographic impact of István Láng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by István Láng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites István Láng more than expected).

Fields of papers citing papers by István Láng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by István Láng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by István Láng. The network helps show where István Láng may publish in the future.

Co-authors

The 25 scholars most cited alongside István Láng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with István Láng Line = papers co-authored together István Láng links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 121 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study The Lancet Oncology ·Richard S. Finn, John Crown, István Láng, Katalin Boér, (unknown), Sergey O. Kulyk, Johannes Ettl, Ravindranath Patel, Tamás Pintér, Marcus Schmidt, Yaroslav Shparyk, Anu Thummala, Nataliya L. Voytko, Camilla Fowst, Xin Huang, Sindy T. Kim, Sophia Randolph, Dennis J. Slamon Hit paper breakdown →	2014	1468
2	KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience Journal of Clinical Oncology ·Eric Van Cutsem, István Láng, G D’Haens, Vladimir Moiseyenko, J. Załuski, Gunnar Folprecht, Sabine Tejpar, O. Kisker, Christopher Stroh, P. Rougier	2008	297
3	Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up The Lancet Oncology ·Meredith M. Regan, Patrick Neven, Anita Giobbie‐Hurder, Aron Goldhirsch, Bent Ejlertsen, L. Mauriac, John Forbes, Ian Smith, István Láng, Andrew Wardley, Manuela Rabaglio, Karen N. Price, Richard D. Gelber, Alan S. Coates, Beat Thürlimann	2011	284
4	Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial Journal of Clinical Oncology ·Eric Van Cutsem, Marek P. Nowacki, István Láng, Stefano Cascinu, I. Shchepotin, Joan Maurel, P. Rougier, David Cunningham, Johannes Nippgen, C.-H. Köhne	2007	246
5	Contribution of live fences to the ecological integrity of agricultural landscapes Agriculture Ecosystems & Environment ·Célia A. Harvey, Cristóbal Villanueva, Jaime Villacís, Mario Peña Chacón, Daniel Horna, M J F Lopez, Muhammad Ibrahim, René Maximiliano Gómez, Rachel C. Taylor, (unknown), Alicia Rodríguez Navas, Joel C. Sáenz, Dalia Sánchez, (unknown), Sergio Vílchez, Blas Hernández, Antonio J. Pérez, Fernando Ruiz, Flor Magali Aguiar López, István Láng, Fergus Sinclair	2005	179
6	Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18 Breast Cancer Research ·Richard S. Finn, John Crown, Johannes Ettl, Marcus Schmidt, (unknown), István Láng, Tamás Pintér, Katalin Boér, Ravindranath Patel, Sophia Randolph, Sindy T. Kim, Xin Huang, Patrick Schnell, Sashi Nadanaciva, Cynthia Huang Bartlett, Dennis J. Slamon	2016	140
7	Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: TEXT and SOFT Trials Journal of Clinical Oncology ·Meredith M. Regan, Prudence A. Francis, Olivia Pagani, Gini F. Fleming, Barbara Walley, Giuseppe Viale, Marco Colleoni, István Láng, Henry Gómez, Carlo Tondini, Graziella Pinotti, Karen N. Price, Alan S. Coates, Aron Goldhirsch, Richard D. Gelber	2016	120
8	First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). Journal of Clinical Oncology ·Martine Piccart, Andrew Holmes, José Baselga, Evandro de Azambuja, Amylou C. Dueck, Giuseppe Viale, Jo Anne Zujewski, Aron Goldhirsch, Sergio Santillana, Kathleen I. Pritchard, Antonio C. Wolff, Christian Jackisch, István Láng, Michael Untch, Ian E. Smith, Frances Boyle, Binghe Xu, Henry Gómez, Richard D. Gelber, Edith A. Perez	2014	106
9	Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor–Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy Journal of Clinical Oncology ·Meritxell Bellet, Kathryn P. Gray, Prudence A. Francis, István Láng, Eva Ciruelos, Aňa Lluch, Miguel Ángel Climent, Gustavo Catalán, Antoni Avellà, Uriel Bohn, Antonio González-Martı́n, Roser Ferrer, Roberto Catalán, Analía Azaro, Agnita Rajasekaran, Josefa Morales, Josep Vázquez, Gini F. Fleming, Karen N. Price, Meredith M. Regan	2016	106
10	Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study Journal of Clinical Oncology ·Marco Colleoni, Anita Giobbie‐Hurder, Meredith M. Regan, Beat Thürlimann, Henning T. Mouridsen, L. Mauriac, John Forbes, Robert Paridaens, István Láng, Ian Smith, Jacquie Chirgwin, Tadeusz Pieńkowski, Andrew Wardley, Karen N. Price, Richard D. Gelber, Alan S. Coates, Aron Goldhirsch	2011	104
11	Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study Journal of Clinical Oncology ·Signe Borgquist, Anita Giobbie‐Hurder, Thomas P. Ahern, Judy E. Garber, Marco Colleoni, István Láng, Marc Debled, Bent Ejlertsen, Roger von Moos, Ian C. P. Smith, Alan S. Coates, Aron Goldhirsch, Manuela Rabaglio, Karen N. Price, Richard D. Gelber, Meredith M. Regan, Beat Thürlimann	2017	101
12	Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial Journal of Clinical Oncology ·Irene Wapnir, Karen N. Price, Stewart Anderson, André Robidoux, Miguel Martín, J.W.R. Nortier, Alexander Paterson, Mothaffar F. Rimawi, István Láng, José Manuel Baena-Cañada, Beat Thürlimann, Eleftherios P. Mamounas, Charles E. Geyer, Shari Gelber, Alan S. Coates, Richard D. Gelber, Priya Rastogi, Meredith M. Regan, Norman Wolmark, Stefan Aebi, (unknown), (unknown), (unknown)	2018	92
13	Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy Journal of Clinical Oncology ·Ander Urruticoechea, Mohammed Rizwanullah, Seock‐Ah Im, A. Ruiz, István Láng, Gianluca Tomasello, Hannah Douthwaite, Tanja Badovinac Črnjević, Sarah Heeson, Jennifer Eng‐Wong, Montserrat Muñoz-Mateu	2017	92
14	[Liver-protective action of silymarin therapy in chronic alcoholic liver diseases]. PubMed ·János Fehér, György Deák, Györgyi Műzes, István Láng, V Niederland, K Nékám, M. Kárteszi	1989	88
15	Abstract S3-3: First Results of the NeoALTTO Trial (BIG 01-06/EGF 106903): A Phase III, Randomized, Open Label, Neoadjuvant Study of Lapatinib, Trastuzumab, and Their Combination Plus Paclitaxel in Women with HER2-Positive Primary Breast Cancer Cancer Research ·José Baselga, Ian Bradbury, Holger Eidtmann, Serena Di Cosimo, Claudia Aura, Evandro de Azambuja, Henry Gómez, Phuong Dinh, Karine Fauria, Veerle Van Dooren, Paolo Paoletti, Aron Goldhirsch, T-W Chang, István Láng, Michael Untch, RD Gelber, M. Piccart-Gebhart	2010	83
16	Effect of the bioflavonoid silymarin on the in vitro activity and expression of superoxide dismutase (SOD) enzyme. PubMed ·Györgyi Műzes, György Deák, István Láng, K Nékám, P Gergely, János Fehér	1991	59
17	Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer Clinical Pharmacology & Therapeutics ·B. Adiwijaya, J. Kim, István Láng, Tibor Csőszi, Antonio Cubillo, (unknown), Ma‐Li Wong, J. O. Park, J-S Kim, K-M. Rau, Bohuslav Melichar, JB Gallego, Jonathan B. Fitzgerald, Bruce Belanger, István Molnár, WW Ma	2017	46
18	Safety of everolimus plus exemestane in patients with hormone-receptor–positive, HER2–negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET) Annals of Oncology ·Guy Jérusalem, Gabriella Mariani, Eva Ciruelos, Miguel Martín, Vivianne C. G. Tjan‐Heijnen, P. Neven, J.G. Gavila, Andrea Michelotti, Filippo Montemurro, Daniele Generali, Edda Simoncini, István Láng, Jozef Mardiak, Bjørn Naume, Maura Camozzi, K. Lorizzo, Sara Bianchetti, PierFranco Conte	2016	45
19	Cetuximab plus FOLFIRI: Final data from the CRYSTAL study on the association of KRAS and BRAF biomarker status with treatment outcome. Journal of Clinical Oncology ·Eric Van Cutsem, István Láng, Gunnar Folprecht, Marek P. Nowacki, Carlo Barone, I. Shchepotin, Joan Maurel, David Cunningham, İ. Çeli̇k, Claus Henning Köhne	2010	45
20	[Effect of silimarin (Legalon) therapy on the antioxidant defense mechanism and lipid peroxidation in alcoholic liver disease (double blind protocol)]. PubMed ·Györgyi Műzes, György Deák, István Láng, K Nékám, V Niederland, János Fehér	1990	43

About István Láng

István Láng is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Molecular Biology and Immunology, having authored 121 papers that have together received 4.6k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (23 papers), HER2/EGFR in Cancer Research (16 papers), Breast Cancer Treatment Studies (15 papers), Cancer Treatment and Pharmacology (14 papers), Drug-Induced Hepatotoxicity and Protection (13 papers), Liver Disease Diagnosis and Treatment (9 papers), Pharmacological Effects of Natural Compounds (9 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). The work is most often cited by research in Oncology (2.1k citations), Cancer Research (1.0k citations), Pulmonary and Respiratory Medicine (2.0k citations), Genetics (253 citations) and Pharmacology (213 citations). István Láng has collaborated with scholars based in Hungary, United States and Belgium. Frequent co-authors include Sophia Randolph, John Crown, Richard S. Finn, Katalin Boér, Xin Huang, Sindy T. Kim, Tamás Pintér, Ravindranath Patel, Johannes Ettl and Marcus Schmidt. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, Immunopharmacology and Immunology Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

István Láng

Impact in

Papers in i

In The Last Decade

István Láng

István Láng's Hit Papers

Peers

Countries citing papers authored by István Láng

Fields of papers citing papers by István Láng

All Works

About István Láng

Explore authors with similar magnitude of impact

Papers in